MEDP

Medpace (MEDP) reported Q3 2026 earnings of $4.84 per share, beating consensus estimates of $4.45, with revenues of $716 million exceeding expectations by 1.02%. However, the stock has underperformed the S&P 500 year-to-date, gaining 10.8% versus the market's 12.7%.

The company received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. The Medical Services industry ranks in the bottom 34% of Zacks industries.

In a comparison of two Medical Services stocks, Concentra Group (CON) emerges as the superior value option compared to Medpace (MEDP). CON holds a Zacks Rank of #2 (Buy) with improving earnings outlook and more attractive valuation metrics, including a forward P/E of 22.74 versus MEDP's 34.77, and a PEG ratio of 1.37 versus 2.72. CON also received a Value grade of B compared to MEDP's D grade.

Medpace (MEDP) closed down 1.64% and currently holds a Zacks Rank #3 (Hold) rating. The stock trades at a Forward P/E of 35.35, significantly above the industry average of 17.86, and a PEG ratio of 2.77 versus the industry average of 1.67. While earnings are expected to grow 15.28% next quarter and 14.79% for the full year, the premium valuation suggests limited upside potential in the near term.

Medpace stock declined 2.84% on October 6, 2026, underperforming the broader market gains. The company is expected to report earnings on October 21 with projected EPS of $4.45 (up 15.28% YoY) and revenue of $708.75 million (up 7.4% YoY). However, the stock trades at a premium valuation with a Forward P/E of 35.38 versus the industry average of 16.59, and holds a Zacks Rank of #3 (Hold).

Medpace (MEDP) closed at $622.11, up 1% and outperforming the S&P 500. The clinical development services provider is expected to report Q3 2026 earnings of $4.45 per share (up 15.28% YoY) with revenue of $708.75 million (up 7.4% YoY). However, the stock trades at a Forward P/E of 35.12, significantly above the industry average of 16.95, and carries a Zacks Rank #3 (Hold) rating with no recent estimate revisions.

Medpace reported record net new business awards in Q3 2026, with ending backlog reaching $3.2 billion. The shift in cancellation drivers from funding shortages to clinical failures signals a healthier market. Management deferred 2027 guidance to February but expressed confidence in Q4 performance and normalized competitive pricing.